Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer

Papers of special note have been highlighted as: • of interest •• of considerable interest

References

• 1  Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet365(9472),1687–1717 (2005).
  MedlineGoogle Scholar
• 2  Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol.20(8),1319–1329 (2009).
  Medline CASGoogle Scholar
• 3  Boyages J, Chua B, Taylor R et al. Use of the St Gallen classification for patients with node-negative breast cancer may lead to overuse of adjuvant chemotherapy. Br. J. Surg.89(6),789–796 (2002).
  MedlineGoogle Scholar
• 4  Harbeck N, Thomssen C. A new look at node-negative breast cancer. Oncologist16(Suppl. 1),51–60 (2011).
  MedlineGoogle Scholar
• 5  De Mascarel I, Bonichon F, Durand M et al. Obvious peritumoral emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers. Eur. J. Cancer34(1),58–65 (1998).•• One of the founding publications regarding the prognostic role of peritumoral vascular invasion in early breast cancer.
  Medline CASGoogle Scholar
• 6  Lee AH, Pinder SE, Macmillan RD et al. Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. Eur. J. Cancer42(3),357–362 (2006).
  Medline CASGoogle Scholar
• 7  Gasparini G, Weidner N, Bevilacqua P et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J. Clin. Oncol.12(3),454–466 (1994).
  Medline CASGoogle Scholar
• 8  Ragage F, Debled M, Macgrogan G et al. Is it useful to detect lymphovascular invasion in lymph node-positive patients with primary operable breast cancer?. Cancer116(13),3093–3101 (2010).
  MedlineGoogle Scholar
• 9  Ejlertsen B, Jensen MB, Rank F et al. Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer. J. Natl Cancer Inst.101(10),729–735 (2009).
  MedlineGoogle Scholar
• 10  Duffy MJ, Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin. Biochem.37(7),541–548 (2004).
  Medline CASGoogle Scholar
• 11  Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer72(1),1–22 (1997).
  Medline CASGoogle Scholar
• 12  Look MP, van Putten WL, Duffy MJ et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J. Natl Cancer Inst.94(2),116–128 (2002).•• Meta-analysis providing the more accurate evaluation of the prognostic impact of the uPA/PAI-1 complex in early breast cancer patients.
  Medline CASGoogle Scholar
• 13  Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol.25(33),5287–5312 (2007).• Evidence-based recommendations for the use of tumor markers in breast cancer care.
  Medline CASGoogle Scholar
• 14  Manders P, Tjan-Heijnen VC, Span PN et al. Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer. Cancer Res.64(2),659–664 (2004).• Addresses the predictive value of the uPA/PAI-1 complex in early breast cancer.
  Medline CASGoogle Scholar
• 15  Borstnar S, Sadikov A, Mozina B, Cufer T. High levels of uPA and PAI-1 predict a good response to anthracyclines. Breast Cancer Res. Treat121(3),615–624 (2010).
  Medline CASGoogle Scholar
• 16  Harbeck N, Kates RE, Look MP et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res.62(16),4617–4622 (2002).
  Medline CASGoogle Scholar
• 17  Pritchard KI. High levels of uPA and PAI-1 predict a good response to anthracyclines. Breast Cancer Res. Treat121(3),625–626 (2010).
  MedlineGoogle Scholar
• 18  De Witte JH, Sweep CG, Klijn JG et al. Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients. Br. J. Cancer79(7–8),1190–1198 (1999).
  Medline CASGoogle Scholar
• 19  Foekens JA, Schmitt M, van Putten WL et al. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res.52(21),6101–6105 (1992).
  Medline CASGoogle Scholar
• 20  van Diest PJ, van der Wall E, Baak JP. Prognostic value of proliferation in invasive breast cancer: a review. J. Clin. Pathol.57(7),675–681 (2004).
  Medline CASGoogle Scholar
• 21  Baak JP, Van Diest PJ, Janssen EA et al. Proliferation accurately identifies the high-risk patients among small, low-grade, lymph node-negative invasive breast cancers. Ann. Oncol.19(4),649–654 (2008).
  Medline CASGoogle Scholar
• 22  Jacot W, Gutowski M, Azria D, Romieu G. Adjuvant early breast cancer systemic therapies according to daily used technologies. Crit. Rev. Oncol. Hematol.82(3),361–369 (2012).
  Medline CASGoogle Scholar
• 23  Sweep CG, Geurts-Moespot J, Grebenschikov N et al. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br. J. Cancer78(11),1434–1441 (1998).
  Medline CASGoogle Scholar
• 24  Janicke F, Prechtl A, Thomssen C et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J. Natl Cancer Inst.93(12),913–920 (2001).•• Only mature randomized trial to date using a tissue biomarker assay in the adjuvant treatment decision process.
  Medline CASGoogle Scholar
• 25  Breast cancer; recommendations for clinical practice of Saint Paul de Vence. Oncologie9(9),593–644 (2007).
  Google Scholar
• 26  Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet351(9114),1451–1467 (1998).
  MedlineGoogle Scholar
• 27  Sundquist M, Thorstenson S, Brudin L, Wingren S, Nordenskjold B. Incidence and prognosis in early onset breast cancer. Breast11(1),30–35 (2002).
  Medline CASGoogle Scholar
• 28  Hery M, Delozier T, Ramaioli A et al. Natural history of node-negative breast cancer: are conventional prognostic factors predictors of time to relapse?. Breast11(5),442–448 (2002).
  MedlineGoogle Scholar
• 29  Harbeck N, Kates RE, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J. Clin. Oncol.20(4),1000–1007 (2002).
  MedlineGoogle Scholar